GTC Biotherapeutics Lands $7,000,000 New Financing
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=6f171dfb-9129-4d0a-ab32-4f9a3d3a2048&Preview=1 - Date
6/16/2010 - Company Name
GTC Biotherapeutics - Mailing Address
175 Crossing Blvd. Framingham, MA 01702 - Company Description
GTC Biotherapeutics develops, produces, and commercializes therapeutic proteins through transgenic animal technology. ATryn, our recombinant form of human antithrombin, is the first transgenically produced protein to be approved anywhere in the world, having recently been approved by the European Commission for the prophylactic treatment of deep vein thrombosis in patients with hereditary antithrombin deficiencies that are undergoing surgical procedures. - Website
http://www.transgenics.com - Transaction Type
Debt - Transaction Amount
$7,000,000 - Transaction Round
Undisclosed - Proceeds Purposes
Proceeds purposes were not disclosed. - M&A Terms
- Venture Investor
Undisclosed
